The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
Efforts highlighted at last week's AACR meeting included new efforts to advance gene expression signatures, improve PD-L1 tests, and calculate MSI across tumor types.
The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.
The firm's has expanded its ctDNA sequencing test to cover 17 genes, enough to provide a readout of microsatellite instability for guiding cancer immunotherapy use.
The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.
Investigators showed that sequencing cell-free DNA could detect microsatellite instability, structural rearrangements, and clonal hematopoiesis in patients with metastatic disease.
Researchers separately found that the assay had high concordance with other techniques in cancers including colorectal and endometrial carcinomas.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.